Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.
Our lead programs include a Tie-2 activator for diabetic macular edema (DME) and a hypoxia-inducible factor 1-α (HIF1-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, recently completed a proof-of-concept, phase 2A study (TIME-2), and the HIF1-α stabilization program is rapidly progressing toward the clinic with first-in-human trials expected to start in early 2016.Learn more...
7/15/15 - Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 TrialRead the press release.
4/9/15 - Aerpio Therapeutics to Present at the 14th Annual Needham Healthcare ConferenceRead the press release.
3/4/15 - Aerpio Therapeutics Announces Publication of Positive Results of Phase 1b/2a Clinical Trial of Novel Tie2 Activator, AKB-9778, for the Treatment of Patients with Diabetic Macular Edema (DME) - TIME-1 StudyRead the press release.